DOI: 10.24075/brsmu.2019.018


Precision oncology: myth or reality?

Slavyanskaya TA1, Salnikova SV2
About authors

1 Peoples' Friendship University of Russia, Moscow, Russia

2 Institute of Immunophysiology, Moscow, Russia

Correspondence should be addressed: Tatiana A. Slavyanskaya
Miklouho-Maclay 6, Moscow, 117198; moc.liamg@ayaksnayvalst

Received: 2018-08-24 Accepted: 2019-03-25 Published online: 2019-03-31

Cancer incidence rates are growing at an alarming pace pressing for the development of innovative personalized approaches to treating this disease. The absence of clinical symptoms in the early stages delays the onset of adequate treatment. Traditional therapies are not always as effective as they should be and do not guarantee long-lasting relapse-free survival. Metastatic cancers pose a particular challenge to healthcare professionals. This review touches upon the immunologic mechanisms underlying the development of malignancies, talks about conventional and innovative therapeutic modalities, such as targeted, gene or specific immunotherapies, and analyzes the literature on the use of different approaches that form a basis for precision oncology.

Keywords: gene therapy, cancer, precision medicine, nonspecific immunotherapy, cytokine therapy, targeted therapy, monoclonal antibodies, immune checkpoints, cancer vaccines, nanotechnologies